172 related articles for article (PubMed ID: 37882947)
1. Pancreatic neuroendocrine tumor progression and resistance to everolimus: the crucial role of NF-kB and STAT3 interplay.
Vitali E; Valente G; Panzardi A; Laffi A; Zerbi A; Uccella S; Mazziotti G; Lania A
J Endocrinol Invest; 2024 May; 47(5):1101-1117. PubMed ID: 37882947
[TBL] [Abstract][Full Text] [Related]
2. Long-term acquired everolimus resistance in pancreatic neuroendocrine tumours can be overcome with novel PI3K-AKT-mTOR inhibitors.
Vandamme T; Beyens M; de Beeck KO; Dogan F; van Koetsveld PM; Pauwels P; Mortier G; Vangestel C; de Herder W; Van Camp G; Peeters M; Hofland LJ
Br J Cancer; 2016 Mar; 114(6):650-8. PubMed ID: 26978006
[TBL] [Abstract][Full Text] [Related]
3. The selective PI3Kα inhibitor BYL719 as a novel therapeutic option for neuroendocrine tumors: Results from multiple cell line models.
Nölting S; Rentsch J; Freitag H; Detjen K; Briest F; Möbs M; Weissmann V; Siegmund B; Auernhammer CJ; Aristizabal Prada ET; Lauseker M; Grossman A; Exner S; Fischer C; Grötzinger C; Schrader J; Grabowski P;
PLoS One; 2017; 12(8):e0182852. PubMed ID: 28800359
[TBL] [Abstract][Full Text] [Related]
4. Metformin and Everolimus: A Promising Combination for Neuroendocrine Tumors Treatment.
Vitali E; Boemi I; Tarantola G; Piccini S; Zerbi A; Veronesi G; Baldelli R; Mazziotti G; Smiroldo V; Lavezzi E; Spada A; Mantovani G; Lania AG
Cancers (Basel); 2020 Aug; 12(8):. PubMed ID: 32748870
[TBL] [Abstract][Full Text] [Related]
5. Upregulation of Peroxiredoxin-2 in Well-Differentiated Pancreatic Neuroendocrine Tumors and Its Utility as a Biomarker for Predicting the Response to Everolimus.
Kim EJ; Kim YJ; Lee HI; Jeong SH; Nam HJ; Cho JH
Antioxidants (Basel); 2020 Nov; 9(11):. PubMed ID: 33182509
[TBL] [Abstract][Full Text] [Related]
6. Cancer-Associated Fibroblasts Induce Proliferation and Therapeutic Resistance to Everolimus in Neuroendocrine Tumors through STAT3 Activation.
Amin T; Viol F; Krause J; Fahl M; Eggers C; Awwad F; Schmidt B; Benten D; Ungefroren H; Fraune C; Clauditz TS; Sauter G; Izbicki JR; Lohse AW; Huber S; Schrader J
Neuroendocrinology; 2023; 113(5):501-518. PubMed ID: 36473454
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and Safety of Everolimus in Extrapancreatic Neuroendocrine Tumor: A Comprehensive Review of Literature.
Faggiano A; Malandrino P; Modica R; Agrimi D; Aversano M; Bassi V; Giordano EA; Guarnotta V; Logoluso FA; Messina E; Nicastro V; Nuzzo V; Sciaraffia M; Colao A
Oncologist; 2016 Jul; 21(7):875-86. PubMed ID: 27053503
[TBL] [Abstract][Full Text] [Related]
8. JAK2 inhibitor blocks the inflammation and growth of esophageal squamous cell carcinoma in vitro through the JAK/STAT3 pathway.
Fang J; Chu L; Li C; Chen Y; Hu F; Zhang X; Zhao H; Liu Z; Xu Q
Oncol Rep; 2015 Jan; 33(1):494-502. PubMed ID: 25405520
[TBL] [Abstract][Full Text] [Related]
9. Celecoxib suppresses proliferation and metastasis of pancreatic cancer cells by down-regulating STAT3 / NF-kB and L1CAM activities.
Zuo C; Hong Y; Qiu X; Yang D; Liu N; Sheng X; Zhou K; Tang B; Xiong S; Ma M; Liu Z
Pancreatology; 2018 Apr; 18(3):328-333. PubMed ID: 29525378
[TBL] [Abstract][Full Text] [Related]
10. Emerging use of everolimus in the treatment of neuroendocrine tumors.
Gajate P; Martínez-Sáez O; Alonso-Gordoa T; Grande E
Cancer Manag Res; 2017; 9():215-224. PubMed ID: 28684922
[TBL] [Abstract][Full Text] [Related]
11. Activation of the NF-κB pathway by the STAT3 inhibitor JSI-124 in human glioblastoma cells.
McFarland BC; Gray GK; Nozell SE; Hong SW; Benveniste EN
Mol Cancer Res; 2013 May; 11(5):494-505. PubMed ID: 23386688
[TBL] [Abstract][Full Text] [Related]
12. Gly388Arg FGFR4 Polymorphism Is Not Predictive of Everolimus Efficacy in Well-Differentiated Digestive Neuroendocrine Tumors.
Cros J; Moati E; Raffenne J; Hentic O; Svrcek M; de Mestier L; Sbidian E; Guedj N; Bedossa P; Paradis V; Sauvanet A; Panis Y; Ruszniewski P; Couvelard A; Hammel P
Neuroendocrinology; 2016; 103(5):495-9. PubMed ID: 26335532
[TBL] [Abstract][Full Text] [Related]
13. mTOR inhibitors response and mTOR pathway in pancreatic neuroendocrine tumors.
Falletta S; Partelli S; Rubini C; Nann D; Doria A; Marinoni I; Polenta V; Di Pasquale C; Degli Uberti E; Perren A; Falconi M; Zatelli MC
Endocr Relat Cancer; 2016 Nov; 23(11):883-891. PubMed ID: 27697900
[TBL] [Abstract][Full Text] [Related]
14. WNT5A-ROR2 is induced by inflammatory mediators and is involved in the migration of human ovarian cancer cell line SKOV-3.
Arabzadeh S; Hossein G; Salehi-Dulabi Z; Zarnani AH
Cell Mol Biol Lett; 2016; 21():9. PubMed ID: 28536612
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of mTOR's Catalytic Site by PKI-587 Is a Promising Therapeutic Option for Gastroenteropancreatic Neuroendocrine Tumor Disease.
Freitag H; Christen F; Lewens F; Grass I; Briest F; Iwaszkiewicz S; Siegmund B; Grabowski P
Neuroendocrinology; 2017; 105(1):90-104. PubMed ID: 27513674
[TBL] [Abstract][Full Text] [Related]
16. Expression and Molecular Regulation of the Cox2 Gene in Gastroenteropancreatic Neuroendocrine Tumors and Antiproliferation of Nonsteroidal Anti-Inflammatory Drugs (NSAIDs).
Gao F; Zafar MI; Jüttner S; Höcker M; Wiedenmann B
Med Sci Monit; 2018 Nov; 24():8125-8140. PubMed ID: 30420588
[TBL] [Abstract][Full Text] [Related]
17. NF-kB-dependent activation of STAT3 by H. pylori is suppressed by TFF1.
Soutto M; Bhat N; Khalafi S; Zhu S; Poveda J; Garcia-Buitrago M; Zaika A; El-Rifai W
Cancer Cell Int; 2021 Aug; 21(1):444. PubMed ID: 34419066
[TBL] [Abstract][Full Text] [Related]
18. DRD2 Agonist Cabergoline Abolished the Escape Mechanism Induced by mTOR Inhibitor Everolimus in Tumoral Pituitary Cells.
Mangili F; Esposito E; Treppiedi D; Catalano R; Marra G; Di Muro G; Barbieri AM; Locatelli M; Lania AG; Mangone A; Spada A; Arosio M; Peverelli E; Mantovani G
Front Endocrinol (Lausanne); 2022; 13():867822. PubMed ID: 35721701
[TBL] [Abstract][Full Text] [Related]
19. Combined targeting of STAT3/NF-κB/COX-2/EP4 for effective management of pancreatic cancer.
Gong J; Xie J; Bedolla R; Rivas P; Chakravarthy D; Freeman JW; Reddick R; Kopetz S; Peterson A; Wang H; Fischer SM; Kumar AP
Clin Cancer Res; 2014 Mar; 20(5):1259-73. PubMed ID: 24520096
[TBL] [Abstract][Full Text] [Related]
20. Safety and efficacy of everolimus in adult patients with neuroendocrine tumors.
Oberstein PE; Saif MW
Clin Med Insights Oncol; 2012; 6():41-51. PubMed ID: 22253554
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
